HC Wainwright Predicts Lower Earnings for Oncolytics Biotech

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.41) for the year, down from their previous forecast of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2025 earnings at ($0.10) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday.

Oncolytics Biotech Stock Performance

Shares of TSE:ONC opened at C$1.38 on Monday. The stock has a market capitalization of C$106.07 million, a price-to-earnings ratio of -3.63 and a beta of 1.35. The business’s fifty day moving average price is C$1.50 and its two-hundred day moving average price is C$1.45. Oncolytics Biotech has a fifty-two week low of C$1.15 and a fifty-two week high of C$2.32. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.